10.1111/jphp.12501 33 GuengerichF
Rationale and design of Short-Term EXenatide therapy in Acute ischaemic Stroke (STEXAS): a randomised, open-label, parallel-group study

GLP-1 RAs help by: Decreasing pro-inflammatory cytokine levels Reducing the Psoriasis Area Severity Index (PASI) Improving insulin sensitivity and reducing obesity (both of which exacerbate psoriasis) Wound Healing: In diabetic patients and others with chronic wounds, GLP-1 medications improve healing by: Reducing harmful MMP-9 levels and improving MMP-9/TIMP ratios Enhancing angiogenesis (new blood vessel formation) Normalizing C-reactive protein (CRP) levels, a marker of systemic inflammation Multi-System Anti-Inflammatory Effects of GLP-1 Medications GLP-1 agonists exhibit systemic anti-inflammatory effects across multiple organ systems: Cardiovascular: Reduces arterial plaque, improves endothelial function Renal: Protects glomeruli, reduces proteinuria, slows kidney disease progression Pulmonary: Reduces airway inflammation, potential benefits in asthma and COPD Liver (NAFLD/NASH): Lowers hepatic inflammation, improves liver enzymes GI/Metabolic: Reduces markers like IL-6 and CRP

Sleep-disordered breathing and the current epidemic of obesity: consequence or contributing factor
One missed week results in roughly a 50% reduction in circulating semaglutide, not a complete washout
So why dont the vast majority of Americans know what they are